## 3 Results
### Hematological Changes
Changes in Cytokine--IFN-\(\gamma\), TNF-\(\alpha\), IL-1\(\beta\), IL-6, and IL-12 Content in _Spleen Tissue_  
The CPA control group showed significant (\(p<0.01\)) reductions in splenic IFN-\(\gamma\), TNF-\(\alpha\), IL-1\(\beta\), IL-6, and IL-12 content compared to the normal vehicle control group. However, in all test substance administered groups, including AR\({}_{400}\), the spleen IFN-\(\gamma\), TNF-\(\alpha\), IL-1\(\beta\), IL-6, and IL-12 content increased and were significantly (\(p<0.01\); \(p<0.05\)) higher than those in the CPA control group. In particular, AR groups showed a dose-dependent increase in spleen cytokine levels. In addition, AR\({}_{100}\) group showed an inhibitory effect on the reduction in CPA-induced splenic IFN-\(\gamma\), TNF-\(\alpha\), IL-1\(\beta\), IL-6, and IL-12 levels, comparable to that of the EAP\({}_{200}\) group (Table 6). \begin{table} \begin{tabular}{c c c c c c c} \hline \hline \multirow{2}{*}{**Groups**} & \multicolumn{2}{c}{**Controls**} & \multicolumn{2}{c}{**Reference**} & \multicolumn{2}{c}{**Test Materials**} \\ \cline{2-7}  & **Intact** & **CPA** & **EAP\({}_{200}\)** & **AR\({}_{400}\)** & **AR\({}_{200}\)** & **AR\({}_{100}\)** \\ \hline WBC (K/\(\mu\)L) & 7.61 \(\pm\) 0.48 & 0.55 \(\pm\) 0.14 \({}^{\rm c}\) & 1.09 \(\pm\) 0.10 \({}^{\rm cd}\) & 3.09 \(\pm\) 1.00 \({}^{\rm cd}\) & 2.14 \(\pm\) 0.79 \({}^{\rm cd}\) & 1.08 \(\pm\) 0.15 \({}^{\rm cd}\) \\ \hline Differential count & & & & & & \\ \hline LYM\% & 77.93 \(\pm\) 2.41 & 78.55 \(\pm\) 2.26 & 78.05 \(\pm\) 2.58 & 78.04 \(\pm\) 1.40 & 77.98 \(\pm\) 1.36 & 78.30 \(\pm\) 2.18 \\ NEU\% & 15.71 \(\pm\) 2.37 & 15.74 \(\pm\) 1.91 & 15.79 \(\pm\) 1.94 & 15.88 \(\pm\) 0.97 & 15.73 \(\pm\) 1.71 & 15.50 \(\pm\) 1.75 \\ MONO\% & 3.94 \(\pm\) 1.51 & 4.16 \(\pm\) 1.12 & 4.21 \(\pm\) 1.25 & 4.14 \(\pm\) 1.22 & 4.18 \(\pm\) 1.12 & 4.17 \(\pm\) 1.35 \\ EOS\% & 0.23 \(\pm\) 0.13 & 0.24 \(\pm\) 0.20 & 0.24 \(\pm\) 0.21 & 0.25 \(\pm\) 0.19 & 0.25 \(\pm\) 0.16 & 0.25 \(\pm\) 0.19 \\ BASO\% & 0.31 \(\pm\) 0.14 & 0.30 \(\pm\) 0.12 & 0.31 \(\pm\) 0.14 & 0.28 \(\pm\) 0.15 & 0.30 \(\pm\) 0.15 & 0.31 \(\pm\) 0.14 \\ RBC (M/\(\mu\)L) & 8.42 \(\pm\) 0.60 & 4.95 \(\pm\) 0.44 \({}^{\rm c}\) & 6.25 \(\pm\) 0.26 \({}^{\rm cd}\) & 7.40 \(\pm\) 0.34 \({}^{\rm cd}\) & 6.87 \(\pm\) 0.50 \({}^{\rm cd}\) & 6.24 \(\pm\) 0.25 \({}^{\rm cd}\) \\ HGB (g/dL) & 19.81 \(\pm\) 1.26 & 12.11 \(\pm\) 0.45 \({}^{\rm c}\) & 15.23 \(\pm\) 0.69 \({}^{\rm cd}\) & 17.99 \(\pm\) 1.36 \({}^{\rm d}\) & 16.74 \(\pm\) 0.45 \({}^{\rm cd}\) & 15.16 \(\pm\) 0.72 \({}^{\rm cd}\) \\ HCT (\%) & 44.71 \(\pm\) 1.27 & 27.13 \(\pm\) 1.49 \({}^{\rm a}\) & 34.24 \(\pm\) 1.11 \({}^{\rm ab}\) & 40.46 \(\pm\) 2.08 \({}^{\rm ab}\) & 7.49 \(\pm\) 1.68 \({}^{\rm ab}\) & 34.04 \(\pm\) 1.32 \({}^{\rm ab}\) \\ MCV (fl) & 53.28 \(\pm\) 3.01 & 55.35 \(\pm\) 7.50 & 54.85 \(\pm\) 2.55 & 54.78 \(\pm\) 3.81 & 54.74 \(\pm\) 3.12 & 54.67 \(\pm\) 3.78 \\ MCHC (pg) & 23.68 \(\pm\) 2.70 & 24.63 \(\pm\) 2.35 & 24.38 \(\pm\) 0.88 & 24.34 \(\pm\) 2.00 & 24.49 \(\pm\) 2.00 & 24.32 \(\pm\) 1.37 \\ MCHC (g/dL) & 44.38 \(\pm\) 3.65 & 44.75 \(\pm\) 2.85 & 44.54 \(\pm\) 2.89 & 44.54 \(\pm\) 3.72 & 44.73 \(\pm\) 2.22 & 44.58 \(\pm\) 2.35 \\ PLT (\(\times\)10 K/\(\mu\)L) & 151.45 \(\pm\) 15.57 & 66.19 \(\pm\) 12.30 \({}^{\rm c}\) & 85.33 \(\pm\) 4.14 \({}^{\rm cd}\) & 111.08 \(\pm\) 13.66 \({}^{\rm cd}\) & 99.09 \(\pm\) 9.94 \({}^{\rm cd}\) & 85.38 \(\pm\) 5.45 \({}^{\rm cd}\) \\ \hline \hline \end{tabular}